Y-mAbs Therapeutics is a US based biopharmaceutical company that specializes in the development and commercialization of antibody based therapeutic products for the treatment of cancer, primarily neuroblastoma, small cell lung cancer, and solid tumors. Its flagship product, DANYELZA, is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with high-risk neuroblastoma. In addition, the company is working on several other potential cancer treatments that are still undergoing clinical trials.